‘Be Intentional, Aggressive’ with Ocular Effects of Cancer Drugs

Why It Matters

Ocular toxicity threatens vision and can limit the use of a life‑extending cancer therapy, making proactive eye care essential for patient outcomes. The findings underscore the need for coordinated oncology‑ophthalmology monitoring when using antibody‑drug conjugates.

Key Takeaways

• Mirvetuximab caused corneal microcysts in 3 of 4 ovarian cancer cases
• Early ocular signs appeared after first or second infusion cycle
• Treatment combined steroids, preservative‑free tears, and cyclosporine to mitigate damage
• Dose reductions or cycle holds improved corneal healing in refractory cases
• Collaborative monitoring with oncology is essential for vision preservation

Pulse Analysis

Mirvetuximab (Elahere) represents a new class of antibody‑drug conjugates targeting folate‑receptor‑alpha in platinum‑resistant ovarian and fallopian‑tube cancers. While its cytotoxic payload delivers tumor‑specific killing, recent clinical observations reveal a propensity for off‑target effects on the ocular surface. Early‑stage corneal changes—subepithelial microcysts, superficial punctate keratitis, and stromal haze—typically emerge after the first or second three‑weekly infusion, prompting concerns among both oncologists and eye specialists about preserving visual function while maintaining therapeutic efficacy.

The management strategy highlighted at Optometry’s Meeting emphasizes intentional, aggressive intervention. Preservative‑free artificial tears are administered four times daily, while short courses of topical steroids are applied during the first eight days of each cycle. Adjunctive agents such as cyclosporine, the anti‑inflammatory eye drop Xiidra, and the surface‑stabilizing solution Miebo further mitigate inflammation and epithelial disruption. In refractory cases, clinicians have withheld an infusion or reduced the dose, allowing corneal recovery before resuming treatment. This tiered approach balances the need for continuous cancer control with the imperative to prevent irreversible vision loss.

The broader implication is a call for integrated care pathways that align oncology dosing schedules with ophthalmic surveillance. Utilizing the Common Terminology Criteria for Adverse Events (CTCAE) enables standardized grading of ocular toxicity, facilitating timely dose adjustments and interdisciplinary communication. As antibody‑drug conjugates proliferate across oncology, understanding off‑target cytotoxic mechanisms will inform next‑generation drug design, aiming to retain tumor specificity while minimizing collateral tissue damage. Ultimately, proactive eye care can preserve quality of life and ensure patients reap the full survival benefits of advanced cancer therapies.